Daily Respiratory Research Analysis
Three impactful studies span epidemiology, translational antivirals, and immunology in respiratory health: a 318,282-participant UK Biobank analysis links long-term air pollution exposure to progression from COPD to cardiovascular disease and death; structure-guided inhibitors targeting the SARS-CoV-2 Nsp3 macrodomain advance a novel antiviral class; and multicenter biomarker profiling in CVID identifies serologic and cellular predictors of respiratory infections, complications, and survival.
Summary
Three impactful studies span epidemiology, translational antivirals, and immunology in respiratory health: a 318,282-participant UK Biobank analysis links long-term air pollution exposure to progression from COPD to cardiovascular disease and death; structure-guided inhibitors targeting the SARS-CoV-2 Nsp3 macrodomain advance a novel antiviral class; and multicenter biomarker profiling in CVID identifies serologic and cellular predictors of respiratory infections, complications, and survival.
Research Themes
- Air pollution and cardiopulmonary disease trajectories
- Structure-guided antivirals targeting viral macrodomains
- Biomarker-driven risk stratification in immunodeficiency affecting respiratory infections
Selected Articles
1. Dynamic associations between long-term exposure to ambient air pollution and respiratory-cardiovascular diseases: A trajectory analysis of a prospective study.
In a 318,282-participant UK Biobank cohort with 13.5 years median follow-up, long-term PM2.5, PM10, NO2, and NOx exposures significantly increased adverse transitions along the respiratory-cardiovascular trajectory, including from COPD to CVD and to death. Multi-state models quantified risks per 1 µg/m³ increase, underscoring policy-relevant exposure-response relationships.
Impact: This large-scale, prospective trajectory analysis bridges respiratory and cardiovascular disease progression under real-world air pollution exposure, informing prevention strategies and integrated care for COPD patients.
Clinical Implications: Reinforces the need for air quality interventions and clinician-led risk mitigation (vaccination, pulmonary rehab, aggressive risk factor control) in COPD to reduce downstream CVD events. Supports incorporating environmental exposure into cardiopulmonary risk stratification.
Key Findings
- Long-term PM2.5, PM10, NO2, and NOx exposures were each significantly associated with adverse transitions along the respiratory-cardiovascular trajectory.
- Transition from COPD to CVD showed elevated risk per 1 µg/m³ increase in pollutant exposure.
- Over 13.5 years median follow-up, 6,901 developed COPD, 2,207 progressed to CVD, and 15,921 died, enabling robust multi-state modeling.
Methodological Strengths
- Very large prospective cohort with long median follow-up enabling multi-state trajectory analysis
- Standardized exposure assessment using DEFRA data and residential histories with advanced multi-state modeling
Limitations
- Potential exposure misclassification due to residential-based estimates and lack of personal monitoring
- Residual confounding (e.g., socioeconomic, occupational, indoor exposures) and limited generalizability beyond UK
Future Directions: Validate findings in diverse populations with personal exposure monitoring; integrate co-pollutant and source-apportioned models; test whether air quality policies and COPD integrated care pathways reduce CVD transitions.
BACKGROUND: Exposure to ambient air pollution constitutes a significant risk factor for both chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). However, its impact on the progression of respiratory-cardiovascular disease trajectories, particularly among individuals with COPD, remains unclear. This study aims to assess the associations of long-term air pollution exposure with the progression from a healthy state to the development of COPD, subsequent CVD, and mortality, utilizing a multi-state modeling framework. METHODS: We included 318,282 participants from the UK Biobank who were free of COPD and CVD at baseline in this prospective cohort study. Annual average concentrations of particulate matter (PM₂.₅, PM₁₀) and nitrogen oxides (NO₂, NOₓ), derived from participant residential histories and data from the UK's Department for Environment, Food and Rural Affairs (DEFRA), were used to estimate long-term exposure. Multi-state models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for each 1 µg/m³ increase in air pollutant concentration in relation to disease transitions along the respiratory-cardiovascular trajectory. RESULTS: During a median follow-up period of 13.5 years, 6901 participants developed COPD; 2207 of whom subsequently developed CVD, and 15,921 participants died. All pollutants were significantly associated with adverse transitions in the respiratory-cardiovascular disease trajectory, Adjusted HRs (95 % CIs) per 1 µg/m³ increase in pollutant exposure for the transition from COPD to CVD were: NO CONCLUSION: Chronic exposure to ambient air pollution, particularly PM₂.₅ and PM₁₀, is linked to an elevated risk of progression from COPD to CVD, thereby augmenting the overall burden of respiratory-cardiovascular diseases. These findings highlight the urgent need for effective air quality interventions to reduce pollution-related health impacts.
2. Structure-Based Rational Design of a Selective Hydrolase Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus-2 Nsp3 Macrodomain.
Structure-guided SAR around GS-441524 identified phosphate- and nucleobase-dependent determinants of SARS-CoV-2 Nsp3 macrodomain binding, yielding derivatives with up to 200-fold higher affinity. A sulfamoyl derivative occupying the phosphate subsite formed a stabilizing H-bond network, providing a blueprint for selective macrodomain hydrolase inhibitors.
Impact: Opens a promising antiviral avenue by drugging viral macrodomains that counteract host ADP-ribosylation, with clear structure-activity rules and a potent chemotype for lead optimization.
Clinical Implications: While preclinical, selective Nsp3 macrodomain inhibitors could synergize with polymerase/protease antivirals by restoring innate immune signaling, potentially broadening antiviral portfolios against coronaviruses.
Key Findings
- GS-441524 derivatives achieved up to 200-fold higher affinity for Nsp3 macrodomain versus adenosine-based ligands.
- Phosphate configuration and nucleobase identity critically determine macrodomain binding.
- A sulfamoyl derivative occupying the phosphate subsite forms a stabilizing hydrogen-bond network and shows superior inhibitory potency.
Methodological Strengths
- Comprehensive SAR with a diversified nucleoside analog panel
- Structure-guided design rationalizing subsite occupation and interaction networks
Limitations
- Preclinical biochemical findings without in-cell antiviral efficacy or in vivo validation
- Selectivity and off-target profiling across human macrodomains remain to be fully established
Future Directions: Assess cellular antiviral activity and innate immune restoration; evaluate pharmacokinetics, selectivity across macrodomains, and in vivo efficacy in coronavirus models; explore pan-coronaviral breadth.
Viral macrodomains, which hydrolyze mono-ADP-ribosylated proteins to evade host immunity, represent emerging antiviral targets, yet their druggability remains underexplored. GS-441524, the active metabolite of remdesivir, has been identified as an inhibitor of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) macrodomain (Nsp3b). Herein, the structure-activity relationship governing macrodomain recognition by the ribosylated moiety using a panel of nucleoside analogs, revealing that phosphate configuration and nucleobase identity critically modulate binding affinity. GS-441524 derivatives exhibit up to 200-fold higher affinity compared to adenosine-based ligands. A novel sulfamoyl derivative demonstrates superior inhibitory potency, attributable to its occupation of the phosphate subsite and formation of a stabilizing hydrogen-bond network. These findings provide molecular insights into Nsp3b-ligand interactions and establish a rational framework for the development of high-affinity, structure-guided inhibitors targeting viral macrodomains.
3. Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.
In a multicenter cohort of 209 CVID patients benchmarked to 334 healthy donors, low serum immunoglobulins—especially IgA—predicted susceptibility to respiratory infections, while CD4 T-cell–related immunophenotypes aligned with noninfectious complications, disease severity, and survival. The biomarker set supports risk stratification and monitoring.
Impact: Provides clinically actionable biomarkers linking humoral and cellular immunity to key CVID outcomes, addressing a critical gap in predicting complications and survival—including respiratory infections.
Clinical Implications: Supports incorporating serum IgA and CD4 T-cell immunophenotyping into routine CVID assessment to anticipate respiratory infection risk, identify patients at risk for noninfectious complications, and tailor monitoring intensity and immunomodulation.
Key Findings
- Low serum immunoglobulins, particularly IgA, strongly associated with susceptibility to respiratory infections in CVID.
- CD4 T-cell–related biomarkers aligned with noninfectious complications, disease severity, and overall survival.
- A multicenter cohort (n=209) benchmarked to age-matched healthy donors (n=334) enabled robust reference-based interpretation.
Methodological Strengths
- Multicenter cohort with age-matched healthy reference values
- Integrated serologic, cellular, and molecular biomarker profiling
Limitations
- Observational design limits causal inference; external validation needed
- Moderate sample size and potential center-to-center variability
Future Directions: Prospective validation of biomarker thresholds, integration into risk scores, and testing biomarker-guided monitoring or immunomodulatory strategies to reduce respiratory infections and complications.
BACKGROUND: Common variable immunodeficiency (CVID) includes a heterogeneous group of disorders of predominantly antibody deficiencies featuring infectious and noninfectious complications that might lead to severe organ damage and shortened survival. Appropriate clinical management of CVID has been hampered by the lack of robust biomarkers to predict the development of clinical complications and patient outcome. OBJECTIVE: We investigated the association of individual serologic, cellular, and molecular biomarkers with disease behavior and outcome in CVID. METHODS: A multicenter cohort of 209 CVID patients was studied using age-matched reference values from 334 healthy donors to better define TCD4 RESULTS: Globally, susceptibility to respiratory infections was strongly associated with low serum immunoglobulin (sIg), particularly sIgA, whereas noninfectious complications and disease severity mostly depended on TCD4 CONCLUSION: Our results provide a new set of biomarkers closely associated with infectious and noninfectious complications of CVID, which together predict survival and might contribute to guide patient monitoring and clinical management.